Novartis raised its profit outlook even as a drug trial failure led to a $1.9 billion charge
Core operating income guidance moved from a low-single-digit decline to flat or low-single-digit growth; net income fell 70%
We haven't written up this one. Quartz has the full story — the link below goes straight to it.